Advent Wants to Take Definitive Healthcare Private. The Healthcare Data Layer Is Getting Repriced.

Advent International already controls a majority stake in Definitive Healthcare. Now it has proposed buying the rest for cash and taking the healthcare data company private. The more interesting question is what Advent sees in owning the data layer outright as AI changes how healthcare intelligence is consumed.

Definitive Healthcare may be heading back to private ownership.

In a Schedule 13D filed September 2, Advent International disclosed that it submitted a preliminary, non-binding proposal to acquire the shares and operating-company units it does not already own, at $1.02 per share in cash. Founder and Executive Chairman Jason Krantz would roll his equity into the surviving company rather than cash out.

The proposal still requires review by a special committee and could be modified, withdrawn or never result in a definitive agreement. But the structure matters: this is not a new financial sponsor discovering healthcare data. It is the existing controlling investor attempting to own the remaining economics and remove the company from the public market.

Definitive sits in a strategically important layer

Definitive Healthcare is not an RCM vendor in the traditional sense. It sells healthcare commercial intelligence: provider, organization, affiliation, market and utilization data used by healthcare companies to understand who does what, where, at what scale and within which relationships.

That kind of data becomes more valuable, not less, as generative AI improves.

Models can summarize, search and reason. But they still need reliable underlying data. The quality of the answer increasingly depends on the quality, freshness, normalization and proprietary depth of the information beneath the interface.

That shifts the moat away from the chatbot and toward the dataset.

The public market may be valuing the interface. Advent may be valuing the asset.

A public software company is judged quarter by quarter on growth, margins, retention and guidance. A private owner has more flexibility to rebuild the product, repackage the data, make acquisitions, change pricing and accept near-term disruption in pursuit of a different long-term model.

That distinction matters in healthcare intelligence right now.

The next generation of healthcare-data products may not look like traditional dashboards. They may look like conversational research systems, embedded agents, APIs and automated workflows that sit directly inside strategy, sales, contracting, diligence and operations.

Definitive's underlying data can potentially feed all of those interfaces.

This fits the broader AI shift: proprietary data beats generic intelligence

Frontier models are rapidly commoditizing general reasoning. The scarce inputs are increasingly domain-specific data, workflow access and proprietary outcome history.

For healthcare intelligence companies, that creates a different hierarchy of value:

• Raw proprietary data that others cannot easily reproduce
• Entity resolution and normalization that make fragmented healthcare information usable
• Workflow context that tells the system what decision the user is actually trying to make
• Distribution into the teams that need the answer

The user interface can change. Those underlying assets persist.

There is also a PE operating-model angle

Advent's proposal would potentially delist Definitive Healthcare from Nasdaq and move the company into a structure where product repositioning can happen outside the glare of the public markets.

That could create more room to simplify the portfolio, accelerate AI-native delivery, rethink go-to-market and pursue combinations with adjacent healthcare data or workflow assets.

It also reinforces a pattern RCAI is tracking across healthcare technology: private equity is increasingly willing to own the infrastructure layer underneath AI, not just the application layer sitting on top of it.

What this means for RCM intelligence

The relevance to revenue cycle is indirect but important.

RCM is becoming more data-dependent at exactly the same time that general-purpose AI is becoming more capable. The winners will not necessarily be the companies with the best chat interface. They may be the companies with the deepest proprietary data on payers, providers, reimbursement, policies, transactions and operating performance.

That is why this transaction is worth watching.

If AI lowers the cost of reasoning, the value of differentiated data can rise.

Advent's move on Definitive Healthcare is one more signal that sophisticated investors may be underwriting that future now.